Improving the use of direct oral anticoagulants in atrial fibrillation

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Warfarin's limitations in anticoagulation for atrial fibrillation (AF) spurred the development of direct oral anticoagulants (DOACs).
• DOACs, including thrombin and factor Xa inhibitors, are now recommended by European guidelines for AF management.
• Despite clinical availability, challenges in handling DOACs have emerged.

Purpose of the Study:

• To review the clinical handling, limitations, and uncertainties associated with DOACs in AF patients.
• To highlight areas requiring further research and clinical data for safe DOAC implementation.
• To discuss the real-world challenges of DOAC use, including adherence and monitoring.

Main Methods:

• Literature review of current guidelines and clinical data on DOACs in AF.
• Analysis of limitations and contraindications for DOAC use in specific patient populations.
• Discussion of emerging issues such as patient adherence, monitoring, and bleeding management.

Main Results:

• DOACs have specific contraindications and require caution in patients undergoing ablation, dual antiplatelet therapy, or invasive procedures.
• Limited long-term efficacy and safety data exist, and patient adherence is a significant real-world concern.
• Practical guidelines for monitoring adherence, managing bleeding, and defining therapeutic failures are lacking.

Conclusions:

• Caution and vigilance are necessary for the safe and appropriate use of DOACs as warfarin alternatives in AF.
• Further clinical data are essential to address current uncertainties and improve real-world DOAC management.
• Standardized monitoring, adherence strategies, and bleeding management protocols are needed for DOACs.